VISTIN PHARMA ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.9 NOK | +1.70% |
|
0.00% | +2.58% |
| Apr. 24 | Vistin Pharma ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 24 | Transcript : Vistin Pharma ASA, Q1 2024 Earnings Call, Apr 24, 2024 |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 220 | 330.8 | 461.2 | 773.8 | 859.4 | 700.6 |
| Enterprise Value (EV) 1 | 134.7 | 10.08 | 142.7 | 698.7 | 825 | 748.4 |
| P/E ratio | 3.13 x | -3.57 x | 6.97 x | -7.97 x | 34.6 x | -144 x |
| Yield | - | - | 9.62% | 2.87% | 3.87% | 4.75% |
| Capitalization / Revenue | 1.24 x | 1.65 x | 2.02 x | 3.05 x | 3.08 x | 2.3 x |
| EV / Revenue | 0.76 x | 0.05 x | 0.63 x | 2.75 x | 2.96 x | 2.45 x |
| EV / EBITDA | 17 x | 13.6 x | 5.91 x | 13 x | 19.3 x | 140 x |
| EV / FCF | 2.78 x | 1.76 x | -2.06 x | -15.3 x | -27.1 x | -9.19 x |
| FCF Yield | 35.9% | 56.7% | -48.6% | -6.54% | -3.69% | -10.9% |
| Price to Book | 1.83 x | 0.95 x | 1.12 x | 2.84 x | 3.12 x | 2.56 x |
| Nbr of stocks (in thousands) | 17,055 | 44,345 | 44,345 | 44,345 | 44,345 | 44,345 |
| Reference price 2 | 12.90 | 7.460 | 10.40 | 17.45 | 19.38 | 15.80 |
| Announcement Date | 4/16/18 | 4/26/19 | 4/23/20 | 4/23/21 | 4/27/22 | 4/27/23 |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 177.1 | 200.5 | 228.1 | 253.9 | 278.6 | 304.9 |
| EBITDA 1 | 7.921 | 0.74 | 24.16 | 53.92 | 42.79 | 5.331 |
| EBIT 1 | 5.219 | -4.606 | 16.77 | 45.56 | 33.25 | -6.096 |
| Operating Margin | 2.95% | -2.3% | 7.35% | 17.94% | 11.93% | -2% |
| Earnings before Tax (EBT) 1 | 7.36 | -85.3 | 84.04 | -124.3 | 32 | -6.009 |
| Net income 1 | 70.4 | -73.63 | 66.2 | -96.96 | 24.87 | -4.716 |
| Net margin | 39.76% | -36.72% | 29.02% | -38.19% | 8.92% | -1.55% |
| EPS 2 | 4.128 | -2.089 | 1.493 | -2.190 | 0.5600 | -0.1100 |
| Free Cash Flow 1 | 48.38 | 5.717 | -69.32 | -45.72 | -30.41 | -81.39 |
| FCF margin | 27.33% | 2.85% | -30.39% | -18.01% | -10.92% | -26.7% |
| FCF Conversion (EBITDA) | 610.81% | 772.58% | - | - | - | - |
| FCF Conversion (Net income) | 68.73% | - | - | - | - | - |
| Dividend per Share | - | - | 1.000 | 0.5000 | 0.7500 | 0.7500 |
| Announcement Date | 4/16/18 | 4/26/19 | 4/23/20 | 4/23/21 | 4/27/22 | 4/27/23 |
1NOK in Million2NOK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 47.7 |
| Net Cash position 1 | 85.3 | 321 | 318 | 75.2 | 34.4 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 8.954 x |
| Free Cash Flow 1 | 48.4 | 5.72 | -69.3 | -45.7 | -30.4 | -81.4 |
| ROE (net income / shareholders' equity) | 3.55% | -28.9% | 17.3% | -28.3% | 9.07% | -1.72% |
| ROA (Net income/ Total Assets) | 1.28% | -0.79% | 2.09% | 6.89% | 6.34% | -1.03% |
| Assets 1 | 5,518 | 9,359 | 3,171 | -1,406 | 391.9 | 458.2 |
| Book Value Per Share 2 | 7.050 | 7.870 | 9.320 | 6.140 | 6.220 | 6.160 |
| Cash Flow per Share 2 | 5.000 | 7.230 | 7.210 | 1.740 | 0.8100 | 0.0300 |
| Capex 1 | 35.6 | 18.1 | 18.4 | 53.1 | 31.9 | 64.3 |
| Capex / Sales | 20.08% | 9.01% | 8.05% | 20.91% | 11.46% | 21.09% |
| Announcement Date | 4/16/18 | 4/26/19 | 4/23/20 | 4/23/21 | 4/27/22 | 4/27/23 |
1NOK in Million2NOK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +2.58% | 95.97M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- VISTN Stock
- Financials Vistin Pharma ASA
